A Phase II Study of Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
Latest Information Update: 28 Feb 2023
At a glance
- Drugs Paclitaxel (Primary) ; Tucidinostat (Primary)
- Indications HER2 negative breast cancer
- Focus Therapeutic Use
Most Recent Events
- 17 Feb 2023 Status changed from not yet recruiting to recruiting.
- 05 Dec 2022 New trial record